Navigation Links
Study shows that administering calcium and magnesium effectively reduces neurological sensitivity
Date:5/16/2008

ROCHESTER, Minn. -- Researchers in the North Central Cancer Treatment Group (NCCTG) have shown that patients who receive intravenous calcium and magnesium before and after the chemotherapy drug oxaliplatin for the treatment of advanced colon cancer experience a significantly reduced incidence and severity of neurological side effects (neurotoxicity). This reduction increases the likelihood that patients are able to complete a full course of treatment. The findings were released May 15 as part of the 44th annual meeting of the American Society of Clinical Oncology.

There have been limited studies and anecdotal stories about the effectiveness of calcium plus magnesium in reducing neurotoxicity caused by oxaliplatin, says Daniel Nikcevich, M.D., Ph.D., an oncologist at St. Marys Duluth Clinic in Duluth, Minn., a member of NCCTG and study co-chair.

We designed a double-blind, placebo-controlled study that confirmed the effectiveness of calcium plus magnesium in reducing debilitating neurological sensitivity associated with oxaliplatin, such as pain in the hands, fingers, feet and toes. In the past, these side effects have caused patients to stop treatment and, therefore, not receive critical therapy.

Each year in the United States, 150,000 patients are diagnosed with colon cancer, and approximately 50 percent of those develop advanced colon cancer. Oxaliplatin, in combination with other chemotherapy drugs such as 5-fluorouracil (5-FU), has emerged as a standard-of-care of first-line therapy for advanced colon cancer. However, oxaliplatin can cause both acute and chronic cumulative sensory neurological problems including pain, numbness and tingling that can prevent patients from completing treatment.

In the study, 50 of the 102 patients enrolled received intravenous calcium and magnesium along with oxaliplatin-based chemotherapy, while 52 patients received oxaliplatin-based adjuvant chemotherapy for colon cancer and an intravenous placebo. Study results showed that the use of calcium and magnesium infusions before and after oxaliplatin was associated with a significant decrease in the incidence and severity of neurotoxicity, and it also delayed the time to the onset of neurotoxicity on oxaliplatin therapy.

Calcium and magnesium are an easily administered, safe treatment option for oxaliplatin-induced neurotoxicity. Some initial reports from other studies claimed that the use of calcium and magnesium reduced the activity of oxaliplatin-based chemotherapy, says Axel Grothey, M.D., an oncologist at Mayo Clinic and study co-chair. However, we have definitive results from an independent, blinded radiologic review which demonstrates no negative influence of calcium and magnesium on the outcome for oxaliplatin-based chemotherapy.

Now that we have shown the effectiveness of calcium and magnesium in reducing oxaliplatin-induced neurotoxicity, a further step may be to evaluate the benefit of calcium and magnesium in reducing neurotoxicity caused by other medications, says Dr. Nikcevich. Many other commonly used chemotherapy agents cause neurological sensitivity. By applying our study design, we can test the effectiveness of calcium and magnesium when used with other treatments.

This study was done as part of a program coordinated by Charles Loprinzi, M.D., a medical oncologist at Mayo Clinic Rochester. The program he leads has conducted more than 50 clinical trials designed to find ways to prevent or treat untoward symptoms related to cancer and cancer therapy. This includes three trials to evaluate ways to treat established neuropathy caused by chemotherapy and three additional studies to try to prevent such toxicity. Additional trials are in development to find other ways to alleviate this toxicity.


'/>"/>

Contact: Traci Klein
newsbureau@mayo.edu
507-284-5005
Mayo Clinic
Source:Eurekalert

Related medicine news :

1. ASCO Study Confirms Importance of Histology in Treatment of Non-Small Cell Lung Cancer With ALIMTA (pemetrexed for injection)
2. Study suggests blood test can help improve treatment outcomes for breast cancer patients
3. Study takes a step toward better defining fatigue
4. Having Less Power Impairs the Mind and Ability to Get Ahead, Study Shows
5. Study finds parents use cough medicines on under-2s despite the warnings
6. CardioDynamics Announces Significant ICG Study with Nearly Three Times the National Average Blood Pressure Control Rates at the American Society for Hypertension Annual Scientific Meeting
7. Study Supports Popular HIV Drug Regimen
8. Duska Therapeutics Sponsored University of Pennsylvania Study Demonstrates ATP Improves Sperm Motility and In Vitro Fertilization in Animals
9. Study shows that prostate cancer increases the risk of bone fracture
10. Study Suggests Green Tea May Support the Medical Treatment of Stomach and Colon Cancer
11. Forty-Five Percent of U.S. Employees Have Gained Weight at Their Current Jobs, CareerBuilder.com Study Finds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Bioclinica® ... sponsors and CROs to speed clinical development, has released the industry’s only ... Bioclinica AGILE RTSM provides seamless clinical supply forecasting and management together ...
(Date:4/25/2017)... KY (PRWEB) , ... April 25, 2017 , ... ... announce they have signed an agreement to be the preferred physical therapy provider ... injuries and returning them to Derby City CrossFit as quickly and effectively as ...
(Date:4/25/2017)... ... April 25, 2017 , ... A recent report from the ... for the 2015-16 school year across Wisconsin’s public schools, charter schools, and private ... patterns in student test score performance, the report’s limited analyses fail to provide ...
(Date:4/25/2017)... ... 2017 , ... As pharmaceutical companies are held to increasingly ... innovation in drug formulation and manufacturing. CoreRx offers its clients more than ... support of their development and manufacturing goals. , The company was created ...
(Date:4/25/2017)... Scotch Plains, NJ (PRWEB) , ... April 25, 2017 , ... Saad B. Chaudhary, MD ... with the treatment of acute or chronic problems, I focus on preventative care with all ... patient. If you have any questions, always feel free to contact my office and my ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017 Research and Markets has ... Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, ... their offering. ... pharmacogenomics market was valued at US$ 7,167.6 Mn in 2015, ... expanding at a CAGR of 5.6% from 2016 to 2024. ...
(Date:4/19/2017)... , April 19, 2017 /PRNewswire/ - CRH Medical Corporation (TSX: CRH) (NYSE ... Bloom Burton & Co. Healthcare Investor Conference 2017 at the Sheraton ... Edward Wright , Chief Executive Officer of the Company is scheduled ... CFO, Richard Bear and the Chairman of the Board, ... ...
(Date:4/19/2017)... -- Global Surgical Drainage Device Market: Overview ... excess liquid and air. The fluid to be drained ... Surgical drains are used in a wide variety of ... surgery, neurosurgery, plastic surgery etc. Common use of surgical ... fluid e.g. blood or pus. Surgical drains are available ...
Breaking Medicine Technology: